We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Nacuity Pharmaceuticals Stock

Invest in or calculate the value of your shares in Nacuity Pharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

Nacuity Pharmaceuticals Stock (NAPH)

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.

About Nacuity Pharmaceuticals Stock

Founded

2016

Headquarters

Fort Worth, TX, US

Industries

Health Care

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.

Nacuity Pharmaceuticals Management

Leadership team at Nacuity Pharmaceuticals

Chairman

Sanford Hillsberg

Board Director

Halden Conner

Locked Features

Join now and verify your accreditation status to gain access to:

  • Nacuity Pharmaceuticals current valuation
  • Nacuity Pharmaceuticals stock price
  • Available deals in Nacuity Pharmaceuticals and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Nacuity Pharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like Nacuity Pharmaceuticals through EquityZen funds. These investments are made available by existing Nacuity Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Nacuity Pharmaceuticals stock?

Shareholders can sell their Nacuity Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."